SCHEMBL19996549

SCHEMBL19996549

CCNC(=O)C1CNCCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 3/20 0.45
KMT2A Q03164 1/20 0.36
CHRNB2 P17787 3/20 0.36
CHRNA7 P36544 3/20 0.36
CHRNA4 P43681 3/20 0.36
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
AKT2 P31751 1/20 0.35
DPP4 P27487 1/20 0.35
KCNH2 Q12809 1/20 0.34
CYP2C9 P11712 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
TLR2 O60603 2/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
GNAI3 P08754 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6626467 0.87 PRCP (0.53) PRCPCHRNB2CHRNA7CHRNA4CHRNB4
SCHEMBL20215008 0.86
SCHEMBL1072561 0.84 PRCP (0.62) PRCPCHRNB2CHRNA7CHRNA4CHRNB4
SCHEMBL8605472 0.84 PRCP (0.62) PRCPCHRNB2CHRNA7CHRNA4CHRNB4
SCHEMBL24072254 0.82 PRCP (0.72) PRCPGNAI3GNAO1GNAI1
SCHEMBL18402567 0.82 PRCP (0.72) PRCPGNAI3GNAO1GNAI1
SCHEMBL7379054 0.82 PRCP (0.72) PRCPGNAI3GNAO1GNAI1
SCHEMBL10681169 0.81 PRCP (0.42) PRCPKMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL28980916 0.81 HSD17B10 (0.38) PRCPCHRNB2CHRNA7CHRNA4CHRNB4
SCHEMBL1991927 0.80 CHRNB2 (0.47) PRCPCHRNB2CHRNA7CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 CN claimed
US-11147885-B2 ASH1L inhibitors and methods of treatment therewith THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-10-19 US disclosed
US-9926293-B2 Multivalent RAS binding compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-03-27 US disclosed
US-9795603-B2 Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use SIGNAL PHARMACEUTICALS, LLC (US) 2017-10-24 US disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11147885-B2 ASH1L inhibitors and methods of treatment therewith ASH1L, DOT1L, ASH2L PRCP 2953/4885KMT2A 23/4885CHRNB2 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.